IL6 and Kaposi's sarcoma: Similarly, a phase II trial of imatinib in participants with EpKS did not find significant association between the cytokines (IL-6, Rantes, IFN-γ, and basic fibroblast growth factor) analyzed and the KS treatment response [44].